Use the buttons below to learn more about the safety profile for SYMLIN® (pramlintide acetate) injection as seen in clinical trials in patients with type 1 and type 2 diabetes.
SYMLIN® (pramlintide acetate) injection is indicated as an adjunctive treatment in adults with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.
For US Health Care Professionals|Go to Patient Site Register
US Health Care Professionals
Use the buttons below to learn more about the safety profile for SYMLIN® (pramlintide acetate) injection as seen in clinical trials in patients with type 1 and type 2 diabetes.